Outcome of inflammatory bowel disease patients with prior malignancy

Keyphrases

• Inflammatory Bowel Disease 100%
• Prior Malignancy 100%
• Malignancy 50%
• Non-melanoma Skin Cancer 40%
• Disease-related 30%
• Previous Malignancy 20%
• Treatment Options 10%
• Well-defined 10%
• Disease Diagnosis 10%
• Academic Center 10%
• First Exposure 10%
• Immunosuppressive Therapy 10%
• Cancer Recurrence 10%
• Treatment Initiation 10%
• Second Malignancy 10%
• Thiopurines 10%
• Infliximab 10%
• Biological Treatment 10%
• Anti-tumor Necrosis Factor (anti-TNF) 10%
• Anti-tumor Necrosis Factor Agents 10%
• Second Primary Malignancy 10%
• Anti-tumor Necrosis Factor Therapy 10%
• Inflammatory Bowel Disease Treatment 10%

Medicine and Dentistry

• Cancer 100%
• Patient with Inflammatory Bowel Disease 100%
• Inflammatory Bowel Disease 70%
• Non Melanoma Skin Cancer 40%
• Recurrent Disease 20%
• Tumor Necrosis Factor 20%
• Second Cancer 20%
• Cohort Analysis 10%
• Combination Therapy 10%
• Immunosuppressive Treatment 10%
• Cancer Recurrence 10%
• Biological Product 10%
• Infliximab 10%
• Mercaptopurine 10%
• TNF Inhibitor 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Inflammatory Bowel Disease 100%
• Non Melanoma Skin Cancer 36%
• Recurrent Disease 18%
• Tumor Necrosis Factor 18%
• Second Cancer 18%
• Cohort Study 9%
• Tumor Necrosis Factor Inhibitor 9%
• Combination Therapy 9%
• Biological Product 9%
• Cancer Recurrence 9%
• Immunosuppressive Agent 9%
• Mercaptopurine 9%
• Infliximab 9%